Acorda Therapeutics (ACOR) is one of the more interesting biotechnology
companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010.

Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience with current approved product Zanaflex.

These are among the best fundamentals in all of biotech. We reiterate our Outperform rating on the stock.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (UTHR) United Therapeutics Corporation Misses Earnings EstimatesUnited Therapeutics Corporation (UTHR) reported a net income of 21 cents per share in the...
2. (CYTX) Cytori Therapeutics – Bull of the DayWe continue to be very positive on Cytori Therapeutics (CYTX) and believe the company’s Celution...
3. (CTIC) Cell Therapeutics Fails to ImpressWe were disappointed to hear that the US Food and Drug Administration (FDA) has granted...
4. (CTIC) Cell Therapeutics’ Drug Accepted For Review at FDAWe are pleased to hear that the US Food and Drug Administration (FDA) accepted and...
5. (ALTH) Crucial Time for Allos TherapeuticsWe are awaiting the decision of the US Food and Drug Administration’s (FDA) cancer advisory...
6. (CYTX) Cytori Therapeutics – Bull of the DayWe continue to be very positive on Cytori Therapeutics Inc. (CYTX) and believe the company’s...

Search Posts by Tag: ACOR | Acorda Therapeutics Inc | Biotechnology | Healthcare

RSS Feeds by Tag: ACOR | Acorda Therapeutics Inc | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author